Molecular Partners Revenue and Competitors
Estimated Revenue & Valuation
- Molecular Partners's estimated annual revenue is currently $9.5M per year.
- Molecular Partners's estimated revenue per employee is $42,748
- Molecular Partners's current valuation is $1B. (January 2022)
Employee Data
- Molecular Partners has 222 Employees.
- Molecular Partners grew their employee count by 6% last year.
Molecular Partners's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Finance | Reveal Email/Phone |
Molecular Partners Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Molecular Partners?
About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on immuno-oncology and infectious disease. The company conducts research and development both internally and in partnerships with leading pharmaceutical companies and is backed by top biotech investors.
keywords:N/A
N/A
Total Funding
222
Number of Employees
$9.5M
Revenue (est)
6%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Molecular Partners News
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),...
Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 967.0 days. Molecular Partners stock opened at...
Minutes. of the 17th Annual General Meeting of the Shareholders of MOLECULAR PARTNERS AG, held at 2:00 p.m. on 13 April 2022 at Molecular...